GABAA receptor positive allosteric modulator

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Retrieved on: 
Thursday, September 14, 2023
MSD, GABAA receptor positive allosteric modulator, Ion channel, Human, Society, Central nervous system, PAM, Royal Society of Chemistry, Pharmacokinetics, Research, RSC, Society of Chemical Industry, Patient, Chemical industry, DSM-IV codes, Acetylcholine, Merck, Merck & Co., SCI, PAMS, BioScience Research Collaborative, Pharmaceutical industry, Bionomics

MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375.

Key Points: 
  • MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375.
  • Under the 2014 exclusive Research Collaboration and License Agreement, MSD funds all research and clinical development, and worldwide commercialization of any resulting products.
  • This collaboration generated payments of $20M upfront and $10M for a Phase 1 milestone.
  • Bionomics is eligible to receive up to $465M in additional milestone payments for certain development and commercial milestones plus royalties on net sales of licensed drugs.

Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Monday, August 7, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Other Health, PPD, CIV, PD, Prevalence, DSM-IV codes, European Medicines Agency, New Drug Application, Food and Drug Administration, Plasma, Incidence, Patient, GABAA receptor positive allosteric modulator, Neurology, NEST, Tremor, Symantec Endpoint Protection, Spectrum, EMA, Depression, DEA, Growth, FDA, IND, Safety, D, Social, PAM, Deficit spending, NMDA, Rehabilitation, MCI, Zuranolone, Essential tremor, MDD, CRL, Therapy, Epilepsy, Workforce, HD, GABA, SG, Information technology, NDA, Woman, Disorder, Sale, Neuropsychiatry, GABAA, AD, Food, Pharmaceutical industry, Risk management, Medical device, Beauty salon, Nursing, Design, Boilermaker, Biogen, Sage

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2023.
  • We plan to provide greater detail and next steps before the end of the third quarter,” continued Mr. Greene.
  • ZURZUVAE was approved by the FDA in August 2023 as the first-and-only oral treatment specifically indicated for adults with PPD.
  • Net Loss: Net loss was $160.3 million in the second quarter of 2023 compared to $126.3 million in the same period of 2022.

Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Tuesday, May 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Other Health, PPD, CIV, PD, DSM-IV codes, European Medicines Agency, Plasma, Incidence, Patient, GABAA receptor positive allosteric modulator, Neurology, NEST, Tremor, Spectrum, EMA, DEA, Grammatical mood, PDUFA, Growth, FDA, IND, Safety, D, Depression, Social, PAM, Deficit spending, NMDA, Rehabilitation, MCI, Zuranolone, Essential tremor, MDD, Webcast, Therapy, Epilepsy, HD, GABA, SG, Information technology, NDA, Disorder, Neuropsychiatry, GABAA, AD, Medical device, Pharmaceutical industry, Beauty salon, Design, Boilermaker, Biogen, Sage

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2023.
  • In February 2023, Sage and Biogen announced the FDA accepted the filing of an NDA for zuranolone for the treatment of MDD and PPD.
  • The application was granted priority review and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 5, 2023.
  • ET to review its first quarter 2023 financial results and discuss recent corporate updates.

Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Thursday, February 16, 2023
Mental Health, Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Function (mathematics), NDA, PPD, Safety, Priority review, Proceedings of the Institution of Mechanical Engineers, Part B, Neuropsychiatry, Spectrum, Part, Learning, ECNP, D, Social, Memory, Commercialization, Zuranolone, Disorder, Shionogi, Depression, Grammatical mood, American Academy, GABAA, GABA, AD, Rehabilitation, Prescription Drug User Fee Act, HD, R, GABAA receptor positive allosteric modulator, DSM-IV codes, SG, PDUFA, PAM, Tremor, Patient, Incidence, Essential tremor, Webcast, NEST, Therapy, CIV, MDD, Huntington's disease, Epilepsy, Cognition, Woman, PD, MCI, NMDA, American Academy of Neurology, Medical Affairs Bureau, Plasma, Deficit spending, Conference, IND, Pharmaceutical industry, Medical device, Hunting, Design, Beauty salon, Boilermaker, Cryptocurrency, Biogen, Sage

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
  • In 2022, Sage and Biogen advanced commercialization plans for zuranolone through scientific exchange, permitted interactions with payers and disease state education in MDD and PPD.
  • Net Loss: Net loss was $147.1 million for the fourth quarter of 2022 compared to $124.7 million for the same period in 2021.
  • ET to review its fourth quarter and full year 2022 financial results and discuss recent corporate updates.

Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Tuesday, November 8, 2022
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Plasma, Achievement, Risk, MDD, Company, Private Securities Litigation Reform Act, AD, PD, NEST, U.S. Securities and Exchange Commission, Nasdaq, Solution, ECNP, Government budget balance, Congress, European College of Neuropsychopharmacology, D, Rehabilitation, Zuranolone, Neuropsychiatry, GABA, CIV, GABAA receptor positive allosteric modulator, Director, Grammatical mood, Tremor, IND, NDA, GABAA, NMDA, Epilepsy, Webcast, FDA, MCI, Patient, Essential tremor, Binary relation, Spectrum, PPD, SG, Research, Therapy, Safety, Food, Review, File, Disorder, PAM, Board, Neurology, Goal, Incidence, Depression, Security (finance), Fine chemical, Pharmaceutical industry, Medical device, Risk management, Beauty salon, Boilermaker, Management, Air cargo, Sage, Biogen, HD

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the third quarter ended September 30, 2022.
  • We believe zuranolone, if approved, has the potential to deliver a new treatment option for patients, said Barry Greene, Chief Executive Officer at Sage Therapeutics.
  • During the third quarter, Sage announced key leadership changes:
    Laura Gault, M.D., Ph.D., joined Sage as Chief Medical Officer.
  • ET to review its third quarter 2022 financial results and discuss recent corporate updates.

Bionomics reports Full Year Financial Results

Retrieved on: 
Thursday, August 25, 2022
MSD, Partnership, Government budget balance, Central nervous system disease, American depositary receipt, Australian Securities Exchange, Chemistry, Social anxiety disorder, PTSD, US Foods, Module (mathematics), Board, IPO, Food, Food and Drug Administration, Post-traumatic stress disorder, Fast Track, GLOBE, Company, BNO, Bionomics, SAD, GABAA receptor positive allosteric modulator, ASX, BNC210, Social anxiety, CNS, FOR, Patient, Pharmaceutical industry, Nasdaq, Merck

ADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, Nasdaq:BNOX), today announced its financial results for the 12 months ended 30 June 2022.

Key Points: 
  • ADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, Nasdaq:BNOX), today announced its financial results for the 12 months ended 30 June 2022.
  • Bionomics is a clinical stage biopharmaceutical company developing novel, allosteric, ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need.
  • During the fiscal year ended 30 June 2022, Bionomics made several advancements with the ongoing clinical development of BNC210.
  • The MSD collaboration currently includes two candidates that are in early-stage Phase 1 safety and biomarker clinical trials for treating cognitive impairment.

Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Tuesday, August 2, 2022
Mental Health, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Zuranolone, GABAA receptor positive allosteric modulator, Company, Incidence, File, Safety, Lists of diseases, Disorder, Review, Grammatical mood, Security (finance), NEST, Spectrum, Goal, Insomnia, Research, U.S. Securities and Exchange Commission, Neuropsychiatry, CIV, Solution, Government budget balance, PAM, Tremor, Depression, D, Program, Growth, IND, Clinical research associate, PPD, NMDA, Food, REM, Binary relation, GABA, Risk, Webcast, Achievement, Epilepsy, FDA, Particle-size distribution, Nasdaq, Neurology, Sleep, Essential tremor, GABAA, Plasma, Time, SG, PD, Private Securities Litigation Reform Act, NDA, Rehabilitation, Therapy, MDD, Patient, MCI, Fine chemical, Pharmaceutical industry, Risk management, Beauty salon, Boilermaker, Tutoring, Sage, Biogen, HD

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2022.
  • In the second quarter of this year, Sage and its collaborator, Biogen, announced that the SKYLARK Study of zuranolone in PPD met its primary and all key secondary endpoints.
  • Net Loss: Net loss was $126.3 million for the second quarter of 2022 compared to $107.2 million for the same period of 2021.
  • ET to discuss its second quarter 2022 financial results and recent corporate updates.

GABA Receptor Antagonist - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 19, 2019
Health, Pharmaceutical, Branches of biology, Drugs, Chemistry, Biology of obsessive–compulsive disorder, gamma-Aminobutyric acid, Neurotransmitters, GABA receptor antagonist, GABA receptor, Mechanism of action, GABAA receptor positive allosteric modulator

The "GABA Receptor Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "GABA Receptor Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • GABA Receptor Antagonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across GABA Receptor Antagonist development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Offers detailed therapeutic product profiles of GABA Receptor Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine